Slate Confirms $700 Million in Funding, Bezos Investment
Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content.
Slate Auto, the startup electric vehicle manufacturer, today confirmed to Newsweek that the company closed on $700 million in Series B funding in late 2024.
The funding comes from Bezos Expeditions, General Catalyst and TWG Global, among other investors though the amount each firm provided is unconfirmed.
Bezos Expeditions is an American investment firm that manages Amazon founder Jeff Bezos's personal investment portfolio.
General Catalyst, a venture capital firm, has a varied portfolio that also includes cosmetics company Beauty Pie, image software company Canva and online travel search tool Kayak, among others.
TWG Global is a holding company that has other automotive industry investments, most notably Cadillac's Formula 1 team.
A Slate vehicle wrapped in Newsweek camouflage, carrying stacks of Newsweek's World Greatest Auto Disruptors magazines in its bed.
A Slate vehicle wrapped in Newsweek camouflage, carrying stacks of Newsweek's World Greatest Auto Disruptors magazines in its bed.
Slate
Slate aims to disrupt the automotive industry with a new vehicle and way of doing business that focuses on the necessary and gives buyers the power of choice at a budget-conscious price. It unveiled its first model, a battery-electric vehicle (BEV), to the world on April 26 in Long Beach, California.
Though initially sold as a truck, the new Slate BEV can be transformed into an SUV through an accessories package.
The unique truck is a two-seat pickup that will be sold in a single configuration - one bed size and one cab style. Simplicity is key to the design team's approach to the model; its windows crank and there are climate control knobs. There is no infotainment system nor a touchscreen. It wears steel wheels on each corner.
Slate owners also have the option of wrapping their vehicle or having it wrapped by a pro. Customers can choose from three levels of wrap, which is designed to make the vehicle especially personal.
The automaker will host SlateU tutorial videos on its website to instruct owners on how to enhance their model whether through accessory additions or wrapped elements.
The American company will purchase American-made batteries for its electric truck and assemble the model in the U.S.
Slate is led by CEO Chris Barman, Chairman Rod Copes, COO Jeremy Snyder and head of design, Tisha Johnson, among others.
This is a developing story and will be updated as more information is available.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Hill
2 minutes ago
- The Hill
Trump calls for Intel CEO to resign
'The CEO of INTEL is highly CONFLICTED and must resign, immediately,' he wrote on Truth Social. 'There is no other solution to this problem. Thank you for your attention to this problem!' While he offered few details about his call for Tan to step aside, Trump's post comes after Sen. Tom Cotton (R-Ark.) wrote to the semiconductor firm Tuesday about concerns with the CEO's ties to China. Reuters reported earlier this year that the Intel executive had investments in hundreds of Chinese tech firms, at least eight of which have ties to the Chinese military. Cotton also voiced concerns Tuesday about his previous role as CEO of Cadence Design Systems, which pleaded guilty and paid $140 million last month for violating export controls by selling chip design technology to a Chinese military university. 'Intel is required to be a responsible steward of American taxpayer dollars and to comply with applicable security regulations,' the Arkansas senator wrote, underscoring the nearly $8 billion that Intel received as part of the CHIPS and Science Act. 'Mr. Tan's associations raise questions about Intel's ability to fulfill these obligations,' he added.
Miami Herald
21 minutes ago
- Miami Herald
A Wonder Drug Bungles Its Lead
EDITORS NOTE: EDS: REPEATING to RECODE as a Page 1 refer.); (ART ADV: With illustration.); (With: WEIGHT-LOSS-PILL For years, there was no stopping Novo Nordisk, the Danish drugmaker behind Ozempic. Its diabetes drug became a cultural phenomenon for its ability to induce drastic weight loss while also reducing the risk of heart attacks and other serious diseases in people with obesity. Its potential to transform the health care industry made it a darling of the stock market, surging to become the most valuable company in Europe. Then, suddenly, its fortunes took a turn. Novo Nordisk's share price has plummeted more than 50% this year, pushing it out of the Top 10 list of Europe's most valuable companies. The company bewildered analysts in May when it abruptly said it would replace its CEO, and it has seemed unable to keep ahead of competition from American drugmaker Eli Lilly and the prevalence of cheap copycat versions. "The market's got no patience for Novo," said Gareth Powell, the head of health care at Polar Capital, a fund manager. "Sentiment is absolutely dire." It has been a stunning reversal for the company behind a drug that physicians once called a game changer. On Wednesday, Novo Nordisk reported $24 billion in global sales in the first six months of the year, but reiterated that it expects growth to slow in the rest of the year, which it first flagged in a profit warning last week. The company's stock tumbled more, as analysts and investors expressed doubts about whether there was much the company could do to revive its prospects in the short term. Novo Nordisk is "a company with incredible history and capabilities, and they've got a pipeline," Powell said. "It's just the market's putting zero value on it." The Ozempic boom opens a 'can of worms' Novo Nordisk spent nearly a century in relative obscurity, known mostly to diabetes patients and physicians as the producer of half the world's insulin. That changed with Ozempic, the brand name for semaglutide, Novo Nordisk's synthetic version of a hormone known as glucagon-like peptide 1, or GLP-1, which helps the body regulate blood sugar levels. Ozempic, which came onto the market in late 2017, led to substantial weight loss and quickly attracted cultural cachet, not least because of its use among celebrities. TikTok videos documenting people's journey with Ozempic attracted millions of views. Analysts predicted that it could tap into an enormous market, since 1 billion people in the world are considered obese. In the first half of the year, Novo Nordisk made $10 billion in sales from Ozempic, of which 70% was in the United States. For a company that had been focused on the steady business of selling insulin, the popularity of Ozempic took its executives by surprise. In 2021, they started selling Wegovy, semaglutide marketed specifically for weight loss, but demand was so high that the company struggled to meet it. That shortage "opened a whole can of worms," said Rajesh Kumar, an analyst at HSBC. An FDA decision opens the door for copycats In 2022, semaglutide landed on the Food and Drug Administration's shortage list, which spurred production of cheaper copycat versions of Novo Nordisk's drugs. To ensure the supply of medicines facing shortages, U.S. federal law allows companies to produce versions of patented drugs via a process of mixing ingredients called compounding. The FDA said this year that the shortage was over and ordered producers and sellers of the copycat weight-loss drugs to wind down. But Novo Nordisk said that never happened. Compounders have continued to offer what they call "personalized" versions of the drugs, a legally murky practice that they claim is allowed by the law. Novo Nordisk said last week that more than 1 million people were still using compounded GLP-1s, eating into the company's market share and forcing it to slash sales and profit forecasts. Its shares promptly dropped more than 20%, erasing more than $70 billion in market value in a day, and some analysts lowered their recommendations on the company. One of them was Kumar, who had been advising investors buy Novo Nordisk's shares for at least two years before downgrading last week to "hold." Compounding was part of the reason. "Novo is issuing a lot of cease-and-desist orders, but it has been very difficult to stop them," he said, adding that he had never seen compounding at this scale before. On Wednesday, Novo Nordisk said it had filed 14 new lawsuits against compounders the day before. "It's important that we get compounding off the market because right now it has equal size of our business," said Lars Fruergaard Jorgensen, the departing CEO. Compounders, in particular, have targeted Wegovy because it was the most well-known brand, Kumar said. That has helped Eli Lilly to get an edge. Eli Lilly catches up, and then some Novo Nordisk had a huge head start. After Ozempic went on sale, it was another 4 1/2 years before a serious competitor emerged: Eli Lilly's Mounjaro, the brand name for tirzepatide, a drug used to treat diabetes. Mounjaro proved to be more effective, leading to greater weight loss in clinical trials. Many patients said they preferred it. At the start of this year, Eli Lilly's Zepbound, which is tirzepatide marketed for weight loss, passed Wegovy in new prescriptions in the United States, according to IQVIA, an analytics company. Unlike Novo Nordisk, Eli Lilly also found ways to get its product to consumers more cheaply, and compete with telehealth companies offering compounded copycat versions, by selling its drug in vials with syringes instead of the more expensive pens with prefilled doses. Novo Nordisk was further hampered by its slowness in introducing a direct-to-consumer sales platform. NovoCare Pharmacy launched in March, 14 months after LillyDirect. "Lilly was doing all these things, and Novo wasn't," said Emily Field, an analyst at Barclays, who recently downgraded the stock. "It felt like a lot of this was one big own goal," she said. Novo's pipeline struggles to impress More than anything, a company's market value is determined by investors' expectations for earnings in the future. For a pharmaceutical company, that means the drugs in its pipeline. This has helped Eli Lilly's stock outperform Novo Nordisk's this year. Investors and analysts are particularly interested in the prospects of weight-loss pills, which could reach more patients than injections. Eli Lilly's daily pill, orforglipron, has been showing promising results in late-stage clinical trials, with similar weight loss to Novo Nordisk's injections and fewer restrictions on its use. Novo Nordisk's oral tablet leads to less weight loss than its injections, but the company has other pills in development. On Thursday, Eli Lilly said that its orforglipron tablets led to 12% weight loss, slightly less than analysts expected, which dented Eli Lilly's shares and gave Novo Nordisk's a boost. But Eli Lilly also raised its overall earnings forecast for the year, on greater demand for Zepbound. In developing its pipeline, Eli Lilly is "deploying capital and running faster than Novo in a market that isn't going to be patient in any way," said Seamus Fernandez, an analyst at Guggenheim Partners. Can a new leader make a difference? The Novo Nordisk Foundation, which controls Novo Nordisk through its holding company, has also grown impatient. At the foundation's urging, Jorgensen, who had been CEO of the company since Ozempic came onto the market, stepped down. Maziar Mike Doustdar took over the top role Thursday, the first non-Dane to run the company. Doustdar, an Iranian-born Austrian citizen who grew up in the United States, joined the company in 1992, for what he thought would be a summer job making photocopies. "He has a bias for speed, for pace and for action," Helge Lund, the chair of the board of directors, said when announcing Doustdar's appointment. Concerns are mounting that analysts may have overestimated the potential size of the weight-loss market, or at least how easily more people will gain access to these drugs. At the same time, President Donald Trump is pressuring companies to lower drug prices and threatening tariffs on medicines produced abroad, casting a cloud over pharma firms' business models. "I still believe there's a big market," said Powell of Polar Capital, which invests in both Novo Nordisk and Eli Lilly. But broad concerns about the market are hitting Novo Nordisk hardest, he added. There probably isn't anything a new CEO could do to "dramatically change" the outlook in the next one or two years, Powell said. "The reality is what it is," he said. "Lilly's product is seen as better." This article originally appeared in The New York Times. Copyright 2025
Yahoo
26 minutes ago
- Yahoo
From Friendly's server to company owner: How Brix Holdings' new leader draws on his roots
You can find original article here Nrn. Subscribe to our free daily Nrn newsletter. What propels someone from serving breakfast at Friendly's to owning the entire company? For Amol Kohli, now owner of Friendly's parent company Brix Holdings through his investment group Legacy Brands International, the long journey required patience, hard work, and good timing. Kohli comes from a first-generation Indian-American immigrant family and said he was taught the value of hard work at a young age. As a teenager, one of his first jobs was working as a breakfast shift waiter at his local Friendly's on the weekends, where by age 18 he had worked his way up to store manager. Kohli went to business school at Drexel University during a time of economic downturn, and while in school, he received a call from his boss at Friendly's who was acquiring stores and wanted help running the back office. 'When the time came to graduate college, I came out with high marks in finance, and now I had three to four years of experience on the restaurant administrative side,' Kohli said. 'I came to the fork in the road and stuck with what was working. So, when the opportunity came for me to apply to franchise in my early 20s, I did it. … This whole thing has just been a natural evolution.' By 2018, Kohli was the youngest franchisee in the Friendly's system. But as his career as a multi-unit franchisee developed, Kohli had no idea it would lead to ownership of the entire company. 'I realized after becoming a father that there was such a love for Friendly's as a familiar brand,' he said. 'I was able to experience the brand like I never had before in my life. I don't care how many business books you read, you cannot experience interfacing with a decently run Friendly's as a parent until you go to one. And I kept thinking, 'Families need this. We can do better.' … Once I got to 20-30 units, it gave me a voice in the company, but there was no guarantee [the acquisition] was going to happen.' Kohli is developing a strategic plan for Brix Holdings, which, besides Friendly's, also owns Clean Juice, Orange Leaf, Red Mango, Smoothie Factory + Kitchen, Souper Salad, and Humble Donut Co., which includes franchisee success and smart development. 'We're not here to make sharp turns,' he said. 'Let's grow responsibly. My No. 1 priority is for people to know that franchising is a real career path, and not just for millionaires. … We want to build a platform that allows that visibility, exposure, and moderate comfort to those who are looking to be a part of this space.' For Kohli, responsible growth starts with infilling regional markets and then identifying the right new markets for the Brix brands, many of which are not well-known outside of their home states and cities. While he does not want to give specific store growth goals, Kohli said that it makes sense to take things '25 stores at a time.' 'One of the things I love about Brix is that most of the brands are regional but have demonstrated proof of market in other markets,' he said. 'We want to infill the East Coast with Clean Juice and Friendly's, and I think Texas would be a great market to get into. … I think a lot of these brands can be in many neighborhoods throughout the country, but I don't have a hard unit number yet.' Besides development, Kohli wants to focus on preserving the legacy of Brix Holdings' regional brands, particularly Friendly's, while also modernizing them. Friendly's recently began revamping its tech stack, including the launch of a new mobile app through Lunchbox, AI testing, and business intelligence investment. He is also open to acquiring more brands in the future. 'Our No. 1 focus is to continue making sure what we have is good and stays good,' Kohli said. 'Then, as we look to onboard [more brands], we have to think if it strategically makes sense, not just from a dollars perspective, but from an operational one. There's no specific hunt to go spend and acquire in the next six months, but [acquisitions] are definitely in our target range.' Contact Joanna at Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
